Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28340215 | 0.63 | FDPS (0.44) | FDPSADAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL6125409 | 0.61 | FDPS (0.54) | FDPSADAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL28186936 | 0.61 | FDPS (0.43) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28763050 | 0.61 | FDPS (0.46) | FDPSADAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7474436 | 0.61 | ADA (0.42) | FDPSADAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL7787139 | 0.61 | FDPS (0.42) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28779724 | 0.61 | FDPS (0.42) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30341176 | 0.61 | GRM5 (0.46) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL840562 | 0.61 | FDPS (0.46) | FDPSADAALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5633 | 0.61 | FDPS (0.42) | FDPSALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054253-A1 | TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | claimed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010054253-A1 | TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | FDPS 288/4885ADA 631/4885ALDH1A1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.